<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55216">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01754532</url>
  </required_header>
  <id_info>
    <org_study_id>SHA-12-0028</org_study_id>
    <nct_id>NCT01754532</nct_id>
  </id_info>
  <brief_title>Correlation Between Clinical Deterioration in Schizophrenic Patients and Hair Cortisol Levels</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The importance of stress as a possible deteriorating factor for schizophrenic patients is
      well documented. However, this notion is based on subjective experience and retrospective
      psychological analysis.

      A novel method of measuring cortisol using hair has a proven correlation to subjective
      stress in non-clinical as well as psychiatric clinical populations.

      This pilot study will attempt to assess the use of cortisol hair level, as a marker of
      stress, to predict clinical deterioration in schizophrenic patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Positive And Negative Symptoms Score</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>correlation between hair cortisol level change from baseline and PANSS score change from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Positive And Negative Symptoms Score</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>correlation between hair cortisol level change from baseline and PANSS score change from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SANS, CGI, CDS, GAF and QOL Scores</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>correlation between hair cortisol level change from baseline and SANS, CDS, GAF, CGI, and QOL scores change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SANS, CGI, CDS, GAF and QOL Scores</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>correlation between hair cortisol level change from baseline and SANS, CDS, GAF, CGI, and QOL scores change from baseline.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizo-Affective Disorder</condition>
  <arm_group>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hair Sample</intervention_name>
    <description>Analysis of hair cortisol levels</description>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10mg of posterior vertex hair
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Schizophrenia or Schizo-Affective Disorder
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50

          -  Diagnosis of schizophrenia or schizoaffective disorder, made by a senior
             psychiatrist.

          -  Signing an informed consent.

        Exclusion Criteria:

          -  Additional psychiatric diagnosis

          -  Boldness or hair shorter than 1cm

          -  Physiological disturbance in the HPA or the use of steroidal medication

          -  Neurological disease (past or present) or neurosurgery.

          -  Pregnancy

          -  Substantial chronic physical diseases/
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aviv Segev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvata MHC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aviv Segev, MD</last_name>
    <phone>+972-9-7478644</phone>
    <email>aviv.segev@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuval Bloch, MD</last_name>
    <phone>+972-9-7478510</phone>
    <email>yuvalbl@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shalvata MHC</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aviv Segev, MD</last_name>
      <phone>+972-9-7874644</phone>
      <email>aviv.segev@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Aviv Segev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 18, 2012</lastchanged_date>
  <firstreceived_date>December 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shalvata Mental Health Center</investigator_affiliation>
    <investigator_full_name>Aviv Segev</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizo-Affective Disorder</keyword>
  <keyword>Stress</keyword>
  <keyword>Cortisol</keyword>
  <keyword>PANSS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
